• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

Covid 19





























They've already squeezed about as much as they can out of the equipment reps. What was once a lucrative job is now one filled with inexperienced reps because of all the cuts they've made to the compensation.
 




































They had good year, like almost 10% over budget or something like that.
also, previously had some huge issues under old president, new regime. probably trying to look good.